GIBSON DUNN

Gibson Dunn Advised Nextech Ventures and EQT Life Sciences in $183 Million Series C Financing for Electra Therapeutics

Firm News | October 23, 2025

Gibson Dunn advised Nextech Ventures and EQT Life Sciences as co-lead investors in a $183 million Series C financing for Electra Therapeutics, a clinical stage biotechnology company pioneering therapies against novel targets for diseases in immunology and cancer. Our corporate team was led by partners Ryan Murr and Branden Berns and included associates Mark Goldman and Hannah Gonzalez.

Related People

Ryan A. Murr

Branden C. Berns

Mark Goldman

Hannah Gonzalez

Related Capabilities

Life Sciences

© 2026 Gibson, Dunn & Crutcher LLP. All rights reserved. For contact and other information, please visit us at www.gibsondunn.com. | **www.gibsondunn.com**